Apomorphine Shortage: What Providers and Prescribers Need to Know in 2026

Apomorphine (Apokyn, Onapgo) remains the only FDA-approved parenteral dopamine agonist for acute rescue in advanced Parkinson's disease. As prescribing clinicians, understanding the supply environment, prior authorization landscape, and clinical alternatives for 2026 is essential to protecting your patients' continuity of care. This guide provides a clinical overview of current apomorphine availability, documentation best practices, and management strategies when apomorphine access is disrupted.

Current US Supply Status: What Clinicians Need to Know

The FDA has not declared a formal shortage for apomorphine injection in the United States as of 2026. Two manufacturers supply the US market: MDD US Operations (brand Apokyn, Onapgo) and TruPharma (generic apomorphine hydrochloride injection). The availability of a generic has expanded supply and reduced costs for some patients, though access remains limited to specialty pharmacy channels.

Clinicians should be aware of two key developments:

Onapgo launch (February 2025): The first continuous subcutaneous apomorphine infusion device in the US was approved and launched. The TOLEDO study demonstrated a mean reduction of 2.47 hours/day in OFF time versus placebo. Onapgo delivers apomorphine at 1–8 mg/hr continuously over 16 waking hours (mean clinical dose ~4 mg/hr, max 98 mg/day).

Kynmobi (sublingual film) discontinued: Kynmobi has been removed from the US market. Patients previously on sublingual apomorphine should be transitioned to Apokyn injection or Onapgo.

Pharmacology Refresher: Why Apomorphine's Receptor Profile Matters Clinically

Apomorphine is a non-ergoline dopamine agonist with high affinity for D4 receptors and moderate affinity for D2, D3, and D5, as well as D1 and D5 receptor engagement that is considerably greater than selective D2/D3 agonists like pramipexole or ropinirole. This broader receptor profile is clinically relevant:

Retrospective data suggest apomorphine is associated with lower rates of impulse control disorders than oral D2/D3-selective agonists

Some open-label data suggest apomorphine may be relatively better tolerated in patients with neuropsychiatric symptoms and hallucinations

QTc prolongation is dose-dependent and clinically significant—thorough QT studies showed a mean QTcF prolongation of 10 ms at recommended doses

Critical Drug Interaction: 5-HT3 Antagonists Are Contraindicated

One of the most clinically important prescribing considerations is the absolute contraindication of 5-HT3 antagonist antiemetics with apomorphine. Concomitant use of ondansetron, granisetron, dolasetron, palonosetron, or alosetron with apomorphine has been associated with profound hypotension and loss of consciousness. This is not a "use with caution" warning—it is a hard contraindication.

When managing apomorphine-related nausea, prescribe trimethobenzamide 300 mg TID, starting 3 days before the first apomorphine dose. Limit trimethobenzamide to the first 2 months of therapy, as it increases somnolence, dizziness, and fall risk when used long-term with apomorphine.

Prior Authorization: Documentation That Prevents Denials

Apomorphine requires prior authorization from virtually all commercial and Medicare payers. Strong PA documentation is essential. Include:

Diagnosis of advanced Parkinson's disease with documented off episodes despite optimized oral therapy

Current medication regimen and levodopa equivalent dose

Documentation of trial and failure of at least one oral dopamine agonist (if step therapy is required by the plan)

Frequency and clinical severity of off episodes (e.g., patient diary data, UPDRS scores if available)

Absence of 5-HT3 antagonist use and presence of trimethobenzamide prescription

Managing Access Disruptions: Clinical Alternatives

When apomorphine is unavailable due to supply or formulary issues, consider the following approaches in consultation with the patient:

Optimize levodopa regimen: Increase frequency or dose of carbidopa/levodopa. Rytary (extended-release) may provide more consistent plasma levels. Consider adding a COMT inhibitor (entacapone, opicapone) to extend levodopa half-life.

Add or increase an oral dopamine agonist: Pramipexole IR or ropinirole can reduce off-time frequency when added adjunctively, though titration takes 2–4 weeks.

Consider VYALEV (foscarbidopa/foslevodopa): For patients needing continuous subcutaneous delivery, VYALEV (FDA-approved October 2024) provides an alternative infusion approach using a levodopa prodrug.

Caution: Do not abruptly discontinue apomorphine. Abrupt withdrawal has been associated with withdrawal-emergent hyperpyrexia and confusion resembling NMS. If discontinuation is necessary, taper gradually under close supervision.

How medfinder Helps Your Patients and Your Practice

medfinder is a service that calls specialty pharmacies on behalf of patients to find which ones have a specific medication in stock, then texts the results to the patient. For practices treating complex Parkinson's patients who rely on apomorphine, recommending medfinder for providers can reduce the number of urgent calls your office receives from patients who cannot locate their medication. Refer your apomorphine patients to medfinder.com when supply is disrupted.

See our companion post: How to help your patients find apomorphine in stock: A provider's guide.